Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.40 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23673330 | 0.81 | ERN1 (0.49) | MAPTPOLBTUBB1CYP1A1CYP1B1 | |
| SCHEMBL95509 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MAPTPOLBHDAC8TRIM24 | |
| SCHEMBL1311076 | 0.80 | HDAC8 (0.65) | ALDH1A1MAPTPOLBHDAC8TRIM24 | |
| SCHEMBL23673331 | 0.80 | ALDH1A1 (0.53) | ALDH1A1MAPTPOLBPPARGALOX5 | |
| SCHEMBL29227198 | 0.80 | PSEN1 (0.53) | MAPTTUBB1PPARGALOX5PSEN1 | |
| SCHEMBL30873519 | 0.80 | PSEN1 (0.53) | MAPTTUBB1PPARGALOX5PSEN1 | |
| SCHEMBL21370452 | 0.78 | NPC1 (0.61) | ALDH1A1MAPTPOLBHDAC8TRIM24 | |
| SCHEMBL18003435 | 0.78 | MAPT (0.48) | ALDH1A1MAPTPOLBPPARGALOX5 | |
| SCHEMBL5627926 | 0.77 | PSEN1 (0.48) | ALDH1A1MAPTPOLBTUBB1PPARG | |
| SCHEMBL23673332 | 0.77 | POLB (0.47) | MAPTPOLBTUBB1CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1302460-B1 | Indolecarboxylic compounds and their use as pharmaceutical compounds | OREAL (FR) | 2006-08-02 | — | — | EP | disclosed |
| US-6596753-B2 | Effective amount of at least one compound of the indolecarboxylic family, this compound or these compositions being intended to treat disorders associated with overactivity of 5 alpha -reductase. These compositions treat androgen | SOCIETE L'OREAL S.A. (FR) | 2003-07-22 | — | — | US | disclosed |
| EP-1302460-A1 | Indolecarboxylic compounds and their use as pharmaceutical compounds | L'OREAL (FR) | 2003-04-16 | — | — | EP | disclosed |
| US-20030050325-A1 | Novel compounds of the indolecarboxylic family and use thereof | BERNARD BRUNO (FR) | 2003-03-13 | — | — | US | disclosed |
| EP-0964852-B1 | INDOLECARBOXYLIC COMPOUNDS AND THEIR USE AS PHARMACEUTICAL COMPOUNDS | OREAL (FR) | 2003-03-12 | — | — | EP | disclosed |
| US-6448285-B1 | DISORDERS ASSOCIATED WITH OVERACTIVITY OF 5 ALPHA REDUCTASE; ANDROGEN DEPENDENT DISORDERS SUCH AS SEBORRHOEA, ACNE, HIRSUTISM AND/OR ANDROGENIC ALOPECIA | SOCIETE L'OREAL S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
| EP-0964852-A1 | INDOLECARBOXYLIC COMPOUNDS AND THEIR USE AS PHARMACEUTICAL COMPOUNDS | L'OREAL (FR) | 1999-12-22 | — | — | EP | disclosed |
| WO-1999012905-A1 | INDOLECARBOXYLIC COMPOUNDS AND THEIR USE AS PHARMACEUTICAL COMPOUNDS | L'OREAL (FR) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050325-A1 | Novel compounds of the indolecarboxylic family and use thereof | CYP17A1, SRD5A1, SRD5A2 | ALDH1A1 298/4885MAPT 3736/4885POLB 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.